Immune to Cancer: The CRI Blog

Let's spread the word about Immunotherapy! Click to share this page with your community.
Copy Link

Durvalumab Becomes First Immunotherapy Approved for Stage III Lung Cancer

February 20, 2018Arthur N. Brodsky, Ph.D.
Immunotherapy tripled the median progression-free survival rate among lung cancer patients compared to those who received only chemotherapy and radiation

Read More

Filter by:

*Immunotherapy results may vary from patient to patient.